Iovance Biotherapeutics Poised for Strong Market Position and Financial Growth: Buy Rating Affirmed
Iovance Biotherapeutics Second Quarter 2024 Earnings: Beats Expectations
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Market-Moving News for August 9th
Encouraging Jobless Claims Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Friday
Iovance Biotherapeutics: A Strong Buy on Robust Earnings and Promising Clinical Progress
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Express News | Iovance Biotherapeutics Shares Jump 27.7% Premarket After Co Forecasts FY24 Revenue Above Estimates
Iovance Biotherapeutics: A Buoyant Future Backed by Strong Sales Guidance and Q2 Performance
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics | 10-Q: Q2 2024 Earnings Report
Iovance Biotherapeutics Soars More Than 20% After Hours on Q2 Beats
Express News | Iovance Biotherapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Issued Q3 Product Revenue Guidance Above Estimates
What the Options Market Tells Us About Iovance Biotherapeutics
Express News | Iovance Biotherapeutics Sees Q3 2024 Total Product Revenue $53M - $55M Vs $24.59M Est
Iovance Biotherapeutics GAAP EPS of -$0.34 Beats by $0.01, Revenue of $31.1M Beats by $6.54M
Express News | Iovance Biotherapeutics Inc Shares up 32.62% at $10.53 in Extended Trade Following Results, Outlook
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q2 Revenue $31.1M, Vs. Street Est of $24.6M
Express News | Iovance Biotherapeutics Inc - Total Product Revenue Guidance of $53-$55 Mln for 3Q24, $160-$165 Mln for FY24, and $450-$475 Mln for FY25